Middle East respiratory syndrome coronavirus (MERS-CoV) - Surveillance and testing in North England from 2012 to 2019.
Adolescent
Adult
Aged
Aged, 80 and over
Antiviral Agents
/ therapeutic use
Child
Child, Preschool
Coronavirus Infections
/ diagnosis
England
/ epidemiology
Epidemiological Monitoring
Female
Humans
Infant
Influenza, Human
/ diagnosis
Male
Middle Aged
Middle East
Middle East Respiratory Syndrome Coronavirus
/ isolation & purification
Oseltamivir
/ therapeutic use
Polymerase Chain Reaction
Retrospective Studies
Travel-Related Illness
Young Adult
EID
Emerging infectious disease
HCID
High consequence infectious disease
MERS
MERS-CoV
Middle East respiratory syndrome coronavirus
Public health epidemiological surveillance
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
17
10
2019
revised:
22
01
2020
accepted:
22
01
2020
pubmed:
1
2
2020
medline:
25
7
2020
entrez:
1
2
2020
Statut:
ppublish
Résumé
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in Saudi Arabia in 2012 and caused an epidemic in the Middle East. Public Health England (PHE) Manchester is one of the two PHE centres in the UK that perform testing for MERS-CoV. The results of the PHE Manchester MERS surveillance from 2012 to 2019 are presented in this report. Retrospective data were collected for returning travellers from the Middle East fitting the PHE MERS case definition. Respiratory samples were tested for respiratory viruses and MERS-CoV using an in-house RT-PCR assay. Four hundred and twenty-six (426) samples from 264 patients were tested for MERS Co-V and respiratory viruses. No MERS-CoV infections were identified by PCR. Fifty-six percent of samples were PCR positive for viral or bacterial pathogen with Influenza A as the predominant virus (44%). Sixty-two percent of all patients had a pathogen identified with the highest positivity from sputum samples. Patients with multiple samples demonstrated a 100% diagnostic yield. Although no cases of MERS were identified, the majority of patients had Influenza infection for which oseltamivir treatment was indicated and isolation warranted. Sputum samples were the most useful in diagnosing respiratory viruses with a 100% diagnostic yield from patients with multiple samples.
Sections du résumé
BACKGROUND
BACKGROUND
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in Saudi Arabia in 2012 and caused an epidemic in the Middle East. Public Health England (PHE) Manchester is one of the two PHE centres in the UK that perform testing for MERS-CoV. The results of the PHE Manchester MERS surveillance from 2012 to 2019 are presented in this report.
METHODS
METHODS
Retrospective data were collected for returning travellers from the Middle East fitting the PHE MERS case definition. Respiratory samples were tested for respiratory viruses and MERS-CoV using an in-house RT-PCR assay.
RESULTS
RESULTS
Four hundred and twenty-six (426) samples from 264 patients were tested for MERS Co-V and respiratory viruses. No MERS-CoV infections were identified by PCR. Fifty-six percent of samples were PCR positive for viral or bacterial pathogen with Influenza A as the predominant virus (44%). Sixty-two percent of all patients had a pathogen identified with the highest positivity from sputum samples. Patients with multiple samples demonstrated a 100% diagnostic yield.
CONCLUSIONS
CONCLUSIONS
Although no cases of MERS were identified, the majority of patients had Influenza infection for which oseltamivir treatment was indicated and isolation warranted. Sputum samples were the most useful in diagnosing respiratory viruses with a 100% diagnostic yield from patients with multiple samples.
Identifiants
pubmed: 32004690
pii: S1201-9712(20)30046-1
doi: 10.1016/j.ijid.2020.01.043
pmc: PMC7129156
pii:
doi:
Substances chimiques
Antiviral Agents
0
Oseltamivir
20O93L6F9H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
237-244Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Clin Infect Dis. 2017 May 15;64(10):1457-1458
pubmed: 28444154
Euro Surveill. 2013 Mar 14;18(11):20427
pubmed: 23517868
Trop Med Int Health. 2015 Jun;20(6):807-12
pubmed: 25688471
J Infect Dis. 2014 Nov 15;210(10):1590-4
pubmed: 24837403
Int J Infect Dis. 2016 Jun;47:5-9
pubmed: 27321961
J Clin Microbiol. 2012 Jan;50(1):21-4
pubmed: 22090400
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Int J Infect Dis. 2016 Jun;47:10-4
pubmed: 27117200
Emerg Infect Dis. 2014 Nov;20(11):1821-7
pubmed: 25341199
East Mediterr Health J. 2013;19 Suppl 1:S12-8
pubmed: 23888790
J Clin Microbiol. 2000 Apr;38(4):1461-7
pubmed: 10747126
Euro Surveill. 2015 Jun 25;20(25):1-6
pubmed: 26132766
Euro Surveill. 2012 Oct 04;17(40):20290
pubmed: 23078800
Influenza Other Respir Viruses. 2017 Jan;11(1):57-60
pubmed: 27603034
Ann Intern Med. 2014 Mar 18;160(6):389-97
pubmed: 24474051